Prime editing in mice with an engineered pegRNA

CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vascular pharmacology 2024-03, Vol.154, p.107269, Article 107269
Hauptverfasser: Salem, Amr R., Bryant, W. Bart, Doja, Jaser, Griffin, Susan H., Shi, Xiaofan, Han, Weihong, Su, Yunchao, Verin, Alexander D., Miano, Joseph M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 107269
container_title Vascular pharmacology
container_volume 154
creator Salem, Amr R.
Bryant, W. Bart
Doja, Jaser
Griffin, Susan H.
Shi, Xiaofan
Han, Weihong
Su, Yunchao
Verin, Alexander D.
Miano, Joseph M.
description CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.
doi_str_mv 10.1016/j.vph.2023.107269
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2909091252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1537189123001295</els_id><sourcerecordid>2909091252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-2a2a23a1cbe0c28afdaf209792d9b7c282167cc9b0fe139b77e7d215282a577e3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAWxQlmzS-kHiWKyqipdUAUKwthxn0rpqHthJEX_PVCks0SzGd3znSnMIuWR0yihLZ5vprl1POeUCteSpOiJjlkkVi_RGHeM7ETJmmWIjchbChlKWZak6JSORsSRDOSazV-8qiKBwnatXkaujylmIvly3jkwdQb1yNYCHImph9fY8PycnpdkGuDj0Cfm4v3tfPMbLl4enxXwZW0GTLuYGSxhmc6CWZ6YsTMmpkooXKpc44SyV1qqclsAEjiTIgrMEP0yCQkzI9ZDb-uazh9DpygUL262poemD5opiMZ5wtLLBan0TgodSt3iT8d-aUb3npDcaOek9Jz1wwp2rQ3yfV1D8bfyCQcPtYAA8cufA62Ad1BZBebCdLhr3T_wPC3V2aQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2909091252</pqid></control><display><type>article</type><title>Prime editing in mice with an engineered pegRNA</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Salem, Amr R. ; Bryant, W. Bart ; Doja, Jaser ; Griffin, Susan H. ; Shi, Xiaofan ; Han, Weihong ; Su, Yunchao ; Verin, Alexander D. ; Miano, Joseph M.</creator><creatorcontrib>Salem, Amr R. ; Bryant, W. Bart ; Doja, Jaser ; Griffin, Susan H. ; Shi, Xiaofan ; Han, Weihong ; Su, Yunchao ; Verin, Alexander D. ; Miano, Joseph M.</creatorcontrib><description>CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.</description><identifier>ISSN: 1537-1891</identifier><identifier>ISSN: 1879-3649</identifier><identifier>EISSN: 1879-3649</identifier><identifier>DOI: 10.1016/j.vph.2023.107269</identifier><identifier>PMID: 38158001</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; CAPN2 ; CRISPR ; CRISPR-Cas Systems ; DNA - genetics ; Gene Editing - methods ; Mice ; Nucleotides ; Prime editing ; RNA, Guide, CRISPR-Cas Systems</subject><ispartof>Vascular pharmacology, 2024-03, Vol.154, p.107269, Article 107269</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-2a2a23a1cbe0c28afdaf209792d9b7c282167cc9b0fe139b77e7d215282a577e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vph.2023.107269$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38158001$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salem, Amr R.</creatorcontrib><creatorcontrib>Bryant, W. Bart</creatorcontrib><creatorcontrib>Doja, Jaser</creatorcontrib><creatorcontrib>Griffin, Susan H.</creatorcontrib><creatorcontrib>Shi, Xiaofan</creatorcontrib><creatorcontrib>Han, Weihong</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><creatorcontrib>Miano, Joseph M.</creatorcontrib><title>Prime editing in mice with an engineered pegRNA</title><title>Vascular pharmacology</title><addtitle>Vascul Pharmacol</addtitle><description>CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.</description><subject>Animals</subject><subject>CAPN2</subject><subject>CRISPR</subject><subject>CRISPR-Cas Systems</subject><subject>DNA - genetics</subject><subject>Gene Editing - methods</subject><subject>Mice</subject><subject>Nucleotides</subject><subject>Prime editing</subject><subject>RNA, Guide, CRISPR-Cas Systems</subject><issn>1537-1891</issn><issn>1879-3649</issn><issn>1879-3649</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwAWxQlmzS-kHiWKyqipdUAUKwthxn0rpqHthJEX_PVCks0SzGd3znSnMIuWR0yihLZ5vprl1POeUCteSpOiJjlkkVi_RGHeM7ETJmmWIjchbChlKWZak6JSORsSRDOSazV-8qiKBwnatXkaujylmIvly3jkwdQb1yNYCHImph9fY8PycnpdkGuDj0Cfm4v3tfPMbLl4enxXwZW0GTLuYGSxhmc6CWZ6YsTMmpkooXKpc44SyV1qqclsAEjiTIgrMEP0yCQkzI9ZDb-uazh9DpygUL262poemD5opiMZ5wtLLBan0TgodSt3iT8d-aUb3npDcaOek9Jz1wwp2rQ3yfV1D8bfyCQcPtYAA8cufA62Ad1BZBebCdLhr3T_wPC3V2aQ</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Salem, Amr R.</creator><creator>Bryant, W. Bart</creator><creator>Doja, Jaser</creator><creator>Griffin, Susan H.</creator><creator>Shi, Xiaofan</creator><creator>Han, Weihong</creator><creator>Su, Yunchao</creator><creator>Verin, Alexander D.</creator><creator>Miano, Joseph M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202403</creationdate><title>Prime editing in mice with an engineered pegRNA</title><author>Salem, Amr R. ; Bryant, W. Bart ; Doja, Jaser ; Griffin, Susan H. ; Shi, Xiaofan ; Han, Weihong ; Su, Yunchao ; Verin, Alexander D. ; Miano, Joseph M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-2a2a23a1cbe0c28afdaf209792d9b7c282167cc9b0fe139b77e7d215282a577e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>CAPN2</topic><topic>CRISPR</topic><topic>CRISPR-Cas Systems</topic><topic>DNA - genetics</topic><topic>Gene Editing - methods</topic><topic>Mice</topic><topic>Nucleotides</topic><topic>Prime editing</topic><topic>RNA, Guide, CRISPR-Cas Systems</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salem, Amr R.</creatorcontrib><creatorcontrib>Bryant, W. Bart</creatorcontrib><creatorcontrib>Doja, Jaser</creatorcontrib><creatorcontrib>Griffin, Susan H.</creatorcontrib><creatorcontrib>Shi, Xiaofan</creatorcontrib><creatorcontrib>Han, Weihong</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Verin, Alexander D.</creatorcontrib><creatorcontrib>Miano, Joseph M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Vascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salem, Amr R.</au><au>Bryant, W. Bart</au><au>Doja, Jaser</au><au>Griffin, Susan H.</au><au>Shi, Xiaofan</au><au>Han, Weihong</au><au>Su, Yunchao</au><au>Verin, Alexander D.</au><au>Miano, Joseph M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prime editing in mice with an engineered pegRNA</atitle><jtitle>Vascular pharmacology</jtitle><addtitle>Vascul Pharmacol</addtitle><date>2024-03</date><risdate>2024</risdate><volume>154</volume><spage>107269</spage><pages>107269-</pages><artnum>107269</artnum><issn>1537-1891</issn><issn>1879-3649</issn><eissn>1879-3649</eissn><abstract>CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3′-extension that shields the primer-binding site of the pegRNA from nucleolytic attack, demonstrated superior activity over conventional pegRNAs in cultured cells. Here, we show the inability of three-component CRISPR or conventional PE to incorporate a nonsynonymous substitution in the Capn2 gene, expected to disrupt a phosphorylation site (S50A) in CAPN2. In contrast, an epegRNA with the same protospacer correctly installed the desired edit in two founder mice, as evidenced by robust genotyping assays for the detection of subtle nucleotide substitutions. Long-read sequencing demonstrated sequence fidelity around the edited site as well as top-ranked distal off-target sites. Western blotting and histological analysis of lipopolysaccharide-treated lung tissue revealed a decrease in phosphorylation of CAPN2 and notable alleviation of inflammation, respectively. These results demonstrate the first successful use of an epegRNA for germline transmission in an animal model and provide a solution to targeting essential developmental genes that otherwise may be challenging to edit.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38158001</pmid><doi>10.1016/j.vph.2023.107269</doi></addata></record>
fulltext fulltext
identifier ISSN: 1537-1891
ispartof Vascular pharmacology, 2024-03, Vol.154, p.107269, Article 107269
issn 1537-1891
1879-3649
1879-3649
language eng
recordid cdi_proquest_miscellaneous_2909091252
source Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE
subjects Animals
CAPN2
CRISPR
CRISPR-Cas Systems
DNA - genetics
Gene Editing - methods
Mice
Nucleotides
Prime editing
RNA, Guide, CRISPR-Cas Systems
title Prime editing in mice with an engineered pegRNA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T11%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prime%20editing%20in%20mice%20with%20an%20engineered%20pegRNA&rft.jtitle=Vascular%20pharmacology&rft.au=Salem,%20Amr%20R.&rft.date=2024-03&rft.volume=154&rft.spage=107269&rft.pages=107269-&rft.artnum=107269&rft.issn=1537-1891&rft.eissn=1879-3649&rft_id=info:doi/10.1016/j.vph.2023.107269&rft_dat=%3Cproquest_cross%3E2909091252%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2909091252&rft_id=info:pmid/38158001&rft_els_id=S1537189123001295&rfr_iscdi=true